Status:
UNKNOWN
Assessment of the Prevalence of Sarcopenia by CT Scan in Patients Diagnosed With Head & Neck Cancer
Lead Sponsor:
Weprom
Conditions:
Sarcopenia
Cancer of Head and Neck
Eligibility:
All Genders
18+ years
Brief Summary
Sarcopenia is defined by the reduction in skeletal muscle mass and physical performance. It results in a decrease in muscle strength, overall physical activity, walking and the development of balance ...
Eligibility Criteria
Inclusion
- patient over 18 years old,
- affiliated to the social security scheme,
- suffering from locally advanced head \& neck cancer (stages I to IVB) at diagnosis,
- not operable,
- justifying treatment by radiotherapy, whether or not associated with chemotherapy or targeted therapy (eg: monoclonal antibodies, immunotherapy) whatever the proposed modalities.
Exclusion
- patient treated by non-conservative surgery and cervical lymph node dissection making it impossible to assess muscle mass with regard to C3,
- metastatic disease,
- minor patient,
- adult patient under guardianship,
- pregnancy or breastfeeding in progress.
Key Trial Info
Start Date :
October 29 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 30 2022
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04804852
Start Date
October 29 2020
End Date
May 30 2022
Last Update
October 8 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinique Victor Hugo / Centre Jean Bernard
Le Mans, France, 72000